Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug

NCT05203679 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia B

Interventions

GENETIC: Single dose intravenous injection of BBM-H901

Sponsor

Shanghai Xinzhi BioMed Co., Ltd.